AXIM Biotechnologies, Inc. (OTCQB: AXIM) is a biotechnology company that is focused on CBD-based treatments for a whole host of illnesses. Shares of the CBD healthcare company are rallying 17%, through afternoon trading on Tuesday, January 10, 2017. Over the past three months, AXIM Biotechnologies, Inc. has seen average daily volume of 115,261 shares. However, volume of 111,050 shares or dollar volume of $1.33 million, has already exchanged hands in afternoon trading Tuesday.

Shares of AXIM Biotechnologies, Inc. are rallying on Tuesday, after the company announced that its CEO, George E. Anastassov, will be meeting with “business prospects and investors” today at the 9th Annual Biotech Showcase and the 35th J.P. Morgan Annual Healthcare Conference. Both conferences are being held today in San Francisco, California and mark some of the largest biotech conferences of the year. Here is the full press release detailing of the two biotech conferences:

AXIM Biotechnologies, Inc. Press Release:

NEW YORK, Jan. 10, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (AXIM), a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is meeting with business prospects and investors at the Biotech Showcase 9th Annual Conference and the J.P. Morgan 35th Annual Healthcare Conference in San Francisco.

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to meet with investors and pharmaceutical executives at one of the industry’s largest annual healthcare investor conferences.

J.P. Morgan Healthcare Conference is the life science industry’s leading conferences of the year. It brings thousands of investors and executives from around the world to San Francisco where companies share their latest innovations with business partners and investors.

About AXIM Biotechnologies, Inc.

AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.

Add a Comment to this Post

comments